A new agent has been approved by the fda for the treatment of thrombocytopenia associated with chronic immune thrombocytopenia purpura (ITP).
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content